Compare ECOR & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECOR | PPBT |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.0M | 45.3M |
| IPO Year | 2018 | 2014 |
| Metric | ECOR | PPBT |
|---|---|---|
| Price | $6.49 | $4.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $22.00 | N/A |
| AVG Volume (30 Days) | 49.2K | ★ 80.9K |
| Earning Date | 04-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.51 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,182,000.00 | N/A |
| Revenue This Year | $28.92 | N/A |
| Revenue Next Year | $32.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 57.09 | N/A |
| 52 Week Low | $4.16 | $0.41 |
| 52 Week High | $13.81 | $5.18 |
| Indicator | ECOR | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 77.72 |
| Support Level | $4.64 | $0.57 |
| Resistance Level | $6.61 | N/A |
| Average True Range (ATR) | 0.70 | 0.27 |
| MACD | -0.06 | 0.37 |
| Stochastic Oscillator | 25.73 | 79.88 |
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.